Polpharma   Report issue

For profit Phase 3 Phase 4
Founded: Gdansk Poland (1935)
Status: No NME R&D (1935)

Organization Overview

First Clinical Trial
2017
NCT01805804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Polpharma Biologics S.A.

Active Ingredients

Drugs in Phase 4 Trials (1)

valsartan (diovan) (1 trial)

Drugs in Phase 3 Trials (1)

natalizumab (tysabri) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Sclerosis (Phase 3)

Ventricular Remodeling (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2